肠道菌群在血液透析患者心血管疾病中作用及靶向干预研究进展  

Role and targeted intervention of gut microbiota in cardiovascular disease in hemodialysis patients

作　　者：杜军霞 赵小淋 高志远 王曼茜 万楠熙 王浩然 丁潇楠 任琴琴[1] 段颖洁 张冬[1] 朱晗玉[1] DU Junxia;ZHAO Xiaoin;GAO Zhiyuan;WANG Manxi;WAN Nanxi;WANG Haoran;DING Xiaonan;REN Qinqin;DUAN Yingjie;ZHANG Dong;ZHU Hanyu(Department of Nephrology,First Medical Center of Chinese PLA General Hospital,State Key Laboratory of Kidney Diseases,National Clinical Research Center for Kidney Diseases,Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases,Beijing Key Laboratory of Digital Intelligent TCM forthe Prevention and Treatment of Pan-vascular Diseases,Key Disciplines of National Administration of Traditional Chinese Medicine,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心肾脏病医学部肾脏疾病全国重点实验室国家慢性肾病临床医学研究中心重症肾脏疾病器械与中西医药物研发北京市重点实验室数智中医泛血管疾病防治北京市重点实验室国家中医药管理局高水平中医药重点学科,北京100853

出　　处：《中华实用诊断与治疗杂志》2025年第2期184-188,共5页Journal of Chinese Practical Diagnosis and Therapy

基　　金：国家自然科学基金(62271506)。

摘　　要：血液透析是终末期肾病患者的重要治疗方法之一。尿毒症状态、饮食习惯、药物使用及透析治疗本身均可能改变肠道生化环境,导致肠道菌群失衡和血清尿毒症毒素蓄积。肠道菌群代谢产物硫酸吲哚酚和硫酸对甲酚是重要的肠源性尿毒症毒素,这两种物质具有较高的蛋白结合力,使其难以通过传统透析有效清除,在血清中蓄积,从而增加心血管事件风险。本文就血液透析患者肠道菌群及其代谢物变化、与心血管疾病的相关性、以肠道菌群为靶点的干预措施的研究进展作一综述。Hemodialysis is one of the most important treatments for patients with end-stage renal disease.The uremic state,dietary habits,drug use,and dialysis treatment itself may alter the biochemical environment of the gut,which often leads to gut microbiota imbalance and serum uremic toxins accumulation.Indoxyl sulfate and p-cresyl sulfate,the metabolites of gut microbiota,are important gut-derived uremic toxins.These two substances have a high protein-binding capacity and accumulate in serum since they are difficult to be effectively removed by traditional dialysis,which increase the risk of cardiovascular events.This paper reviews the research progress of the changes of gut microbiota and its metabolites in hemodialysis patients,the correlation between gut microbiota and cardiovascular disease,and the intervention measures targeting gut microbiota.

关 键 词：肠道菌群 心血管疾病 血液透析 

分 类 号：R69[医药卫生—泌尿科学]